Abstract
Transcatheter aortic valve replacement (TAVR) use in young patients has recently increased following FDA approval for use in low-risk patients. How TAVR use among young patients may have accelerated in the interval between the FDA approval and the guideline publication remain unknown. We sought to characterize the national trends in aortic valve replacement (AVR) among young patients before and after the low-risk indication approval. Using the National Inpatient Sample data, we conducted a cross-sectional study of patients younger than 65 years of age who underwent TAVR, SAVR, or Ross operations between January 1, 2016, and February 29, 2020. We compared in-hospital mortality before and after the low-risk indication approval to infer whether the expansion occurred among lower-risk strata within the TAVR group in relation to SAVR. We identified 106,340 AVRs, including 13,095 TAVR (12.3%), 63,620 bioprosthetic SAVR (59.8%), 28,370 mechanical SAVR (26.7%), and 1,255 Ross (1.2%). The mean age was 54 (10.9), including 32,775 (30.8%) women. Before and after the low-risk approval, the TAVR share increased at 0.25 (0.03%) and 0.60 (0.09%) per month, respectively (interaction term p-value <0.001). Expansion of TAVR use among young patients around the time of FDA approval in low surgical risk patients serves as a case study to highlight the potential importance of specifying the indicated age group in future FDA approvals of transcatheter valve intervention devices.
Competing Interest Statement
Dr. Geirsson receives a consulting fee from Medtronic and Edwards Lifesciences. All other authors have nothing to disclose.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Yale University School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Dr. Geirsson receives a consulting fee from Medtronic and Edwards Lifesciences.
All other authors have nothing to disclose.
Data Availability
The data will be available upon reasonable request to the corresponding author.
